HRP20100064T1 - Postupci za poboljšanje bioraspoloživosti inhibitora renina - Google Patents
Postupci za poboljšanje bioraspoloživosti inhibitora renina Download PDFInfo
- Publication number
- HRP20100064T1 HRP20100064T1 HR20100064T HRP20100064T HRP20100064T1 HR P20100064 T1 HRP20100064 T1 HR P20100064T1 HR 20100064 T HR20100064 T HR 20100064T HR P20100064 T HRP20100064 T HR P20100064T HR P20100064 T1 HRP20100064 T1 HR P20100064T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxy
- amino
- inhibitor
- aryl
- alkanoic acid
- Prior art date
Links
- 239000002461 renin inhibitor Substances 0.000 title claims abstract 20
- 229940086526 renin-inhibitors Drugs 0.000 title claims abstract 20
- 150000001408 amides Chemical class 0.000 claims abstract 25
- 239000003112 inhibitor Substances 0.000 claims abstract 25
- 150000003839 salts Chemical class 0.000 claims abstract 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract 18
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims abstract 7
- 102100030306 TBC1 domain family member 9 Human genes 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- -1 3-methoxypropoxy Chemical group 0.000 claims 6
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims 6
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical group C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 229950010938 valspodar Drugs 0.000 claims 6
- 108010082372 valspodar Proteins 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uporaba kombinacije inhibitora renina i inhibitora istjecanja proteina, pri čemu je inhibitor renina derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ili njegova farmaceutski prihvatljiva sol, naznačena time, da se koristi za pripravu lijeka, pri čemu inhibitor istjecanja proteina poboljšava bioraspoloživost inhibitora renina, tepri čemu inhibitor istjecanja proteina je inhibitor MDR1. Patent sadrži još 29 patentnih zahtjeva.
Claims (30)
1. Uporaba kombinacije inhibitora renina i inhibitora istjecanja proteina, pri čemu je inhibitor renina derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ili njegova farmaceutski prihvatljiva sol, naznačena time, da se koristi za pripravu lijeka,
pri čemu inhibitor istjecanja proteina poboljšava bioraspoloživost inhibitora renina, te
pri čemu inhibitor istjecanja proteina je inhibitor MDR1.
2. Uporaba u skladu sa zahtjevom 1, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ima formulu
[image]
gdje
R1 je C1-4alkoksi-C1-4alkoksi ili C1-4alkoksi-C1-4alkil;
R2 je C1-4alkil ili C1-4alkoksi; te
R3 i R4 su neovisno razgranati C1-4alkil;
ili je njegova farmaceutski prihvatljiva sol.
3. Uporaba u skladu sa zahtjevom 2, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
4. Uporaba u skladu sa zahtjevom 3, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je (2S, 4S, 5S, 7S)-5-amino-4-hidroksi-2-izopropil-7-[4-metoksi-3-(3-metoksi-propoksi)-benzil]-8-metil-nonanoične kiseline (2-karbamoil-2-metil-propil)-amid hemifumarat.
5. Uporaba u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da MDR1 inhibitor je PSC833.
6. Uporaba kombinacije inhibitora renina i inhibitora istjecanja proteina, pri čemu inhibitor istjecanja proteina je PSC833, naznačena time, da se koristi pripravu lijeka,
pri čemu inhibitor istjecanja proteina poboljšava bioraspoloživost inhibitora renina.
7. Uporaba u skladu sa zahtjevom 6, naznačena time, da inhibitor renina je derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline, ili je njegova farmaceutski prihvatljiva sol.
8. Uporaba u skladu sa zahtjevom 7, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ima formulu
[image]
gdje
R1 je C1-4alkoksi-C1-4alkoksi ili C1-4alkoksi-C1-4alkil;
R2 je C1-4alkil ili C1-4alkoksi; te
R3 i R4 su neovisno razgranati C1-4alkil;
ili je njegova farmaceutski prihvatljiva sol.
9. Uporaba u skladu sa zahtjevom 8, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
10. Uporaba u skladu sa zahtjevom 9, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je (2S, 4S, 5S, 7S)-5-amino-4-hidroksi-2-izopropil-7-[4-metoksi-3-(3-metoksi-propoksi)-benzil]-8-metil-nonanoične kiseline (2-karbamoil-2-metil-propil)-amid hemifumarat.
11. Farmaceutski pripravak, naznačen time, da sadrži terapeutski učinkovitu količinu inhibitora renina u kombinaciji s inhibitorom istjecanja proteina, pri čemu je navedeni inhibitor istjecanja proteina prisutan u količini takvoj da se nakon primjene bioraspoloživost inhibitora renina poboljša najmanje 5%, pri čemu inhibitor renina je derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ili je to njegova farmaceutski prihvatljiva sol, te pri čemu inhibitor istjecanja proteina je MDR1 inhibitor.
12. Farmaceutski pripravak u skladu sa zahtjevom 11, naznačen time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ima formulu
[image]
gdje
R1 je C1-4alkoksi-C1-4alkoksi ili C1-4alkoksi-C1-4alkil;
R2 je C1-4alkil ili C1-4alkoksi; te
R3 i R4 su neovisno razgranati C1-4alkil;
ili je njegova farmaceutski prihvatljiva sol.
13. Farmaceutski pripravak u skladu sa zahtjevom 12, naznačen time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
14. Farmaceutski pripravak u skladu sa zahtjevom 13, naznačen time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je (2S, 4S, 5S, 7S)-5-amino-4-hidroksi-2-izopropil-7-[4-metoksi-3-(3-metoksi-propoksi)-benzil]-8-metil-nonanoične kiseline (2-karbamoil-2-metil-propil)-amid hemifumarat.
15. Farmaceutski pripravak u skladu s bilo kojim zahtjevom 11 do 14, naznačen time, da MDR1 inhibitor je PSC833.
16. Farmaceutski pripravak, naznačen time, da sadrži terapeutski učinkovitu količinu inhibitora renina u kombinaciji s inhibitorom istjecanja proteina, pri čemu je navedeni inhibitor istjecanja proteina prisutan u količini takvoj da se nakon primjene bioraspoloživost inhibitora renina poboljša najmanje 5%, pri čemu inhibitor istjecanja proteina je PSC833.
17. Farmaceutski pripravak u skladu sa zahtjevom 16, naznačen time, da inhibitor renina je derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ili je njegova farmaceutski prihvatljiva sol.
18. Farmaceutski pripravak u skladu sa zahtjevom 17, naznačen time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ima formulu
[image]
gdje
R1 je C1-4alkoksi-C1-4alkoksi ili C1-4alkoksi-C1-4alkil;
R2 je C1-4alkil ili C1-4alkoksi; te
R3 i R4 su neovisno razgranati C1-4alkil;
ili je njegova farmaceutski prihvatljiva sol.
19. Farmaceutski pripravak u skladu sa zahtjevom 18, naznačen time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
20. Farmaceutski pripravak u skladu sa zahtjevom 19, naznačen time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je (2S, 4S, 5S, 7S)-5-amino-4-hidroksi-2-izopropil-7-[4-metoksi-3-(3-metoksi-propoksi)-benzil]-8-metil-nonanoične kiseline (2-karbamoil-2-metil-propil)-amid hemifumarat.
21. Uporaba inhibitora istjecanja proteina u poboljšanju bioraspoloživosti inhibitora renina, naznačena time, da inhibitor renina je derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ili njegova farmaceutski prihvatljiva sol, te pri čemu inhibitor istjecanja proteina je inhibitor MDR1.
22. Uporaba u skladu sa zahtjevom 21, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ima formulu
[image]
gdje
R1 je C1-4alkoksi-C1-4alkoksi ili C1-4alkoksi-C1-4alkil;
R2 je C1-4alkil ili C1-4alkoksi; te
R3 i R4 su neovisno razgranati C1-4alkil;
ili je njegova farmaceutski prihvatljiva sol.
23. Uporaba u skladu sa zahtjevom 22, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
24. Uporaba u skladu sa zahtjevom 23, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je (2S, 4S, 5S, 7S)-5-amino-4-hidroksi-2-izopropil-7-[4-metoksi-3-(3-metoksi-propoksi)-benzil]-8-metil-nonanoične kiseline (2-karbamoil-2-metil-propil)-amid hemifumarat.
25. Uporaba u skladu s bilo kojim zahtjevom 21 do 24, naznačena time, da MDR1 inhibitor je PSC833.
26. Uporaba inhibitora istjecanja proteina u poboljšanju bioraspoloživosti inhibitora renina ili njegove farmaceutski prihvatljive soli, naznačena time, da inhibitor istjecanja proteina je PSC833.
27. Uporaba u skladu sa zahtjevom 26, naznačena time, da inhibitor renina je derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline, ili je njegova farmaceutski prihvatljiva sol.
28. Uporaba u skladu sa zahtjevom 27, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline ima formulu
[image]
gdje
R1 je C1-4alkoksi-C1-4alkoksi ili C1-4alkoksi-C1-4alkil;
R2 je C1-4alkil ili C1-4alkoksi; te
R3 i R4 su neovisno razgranati C1-4alkil;
ili je njegova farmaceutski prihvatljiva sol.
29. Uporaba u skladu sa zahtjevom 28, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
30. Uporaba u skladu sa zahtjevom 29, naznačena time, da derivat amida δ-amino-γ-hidroksi-ω-aril-alkanoične kiseline je (2S, 4S, 5S, 7S)-5-amino-4-hidroksi-2-izopropil-7-[4-metoksi-3-(3-metoksi-propoksi)-benzil]-8-metil-nonanoične kiseline (2-karbamoil-2-metil-propil)-amid hemifumarat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59870004P | 2004-08-03 | 2004-08-03 | |
| PCT/EP2005/008369 WO2006013094A1 (en) | 2004-08-03 | 2005-08-02 | Methods for improving bioavailability of a renin inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100064T1 true HRP20100064T1 (hr) | 2010-03-31 |
Family
ID=35056890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100064T HRP20100064T1 (hr) | 2004-08-03 | 2010-02-02 | Postupci za poboljšanje bioraspoloživosti inhibitora renina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7709532B2 (hr) |
| EP (2) | EP1776099B1 (hr) |
| JP (1) | JP5134366B2 (hr) |
| KR (1) | KR20070040384A (hr) |
| CN (1) | CN1993116B (hr) |
| AR (1) | AR050043A1 (hr) |
| AT (1) | ATE449601T1 (hr) |
| AU (1) | AU2005268844B2 (hr) |
| BR (1) | BRPI0514021A (hr) |
| CA (1) | CA2572743C (hr) |
| CY (1) | CY1109826T1 (hr) |
| DE (1) | DE602005017905D1 (hr) |
| DK (1) | DK1776099T3 (hr) |
| EC (1) | ECSP077169A (hr) |
| ES (1) | ES2335597T3 (hr) |
| HR (1) | HRP20100064T1 (hr) |
| IL (1) | IL180678A (hr) |
| MA (1) | MA28821B1 (hr) |
| MX (1) | MX2007001339A (hr) |
| MY (1) | MY142180A (hr) |
| NO (1) | NO20071142L (hr) |
| NZ (1) | NZ552903A (hr) |
| PE (1) | PE20060416A1 (hr) |
| PL (1) | PL1776099T3 (hr) |
| PT (1) | PT1776099E (hr) |
| RU (1) | RU2404758C2 (hr) |
| SI (1) | SI1776099T1 (hr) |
| TN (1) | TNSN07038A1 (hr) |
| TW (1) | TW200616610A (hr) |
| WO (1) | WO2006013094A1 (hr) |
| ZA (1) | ZA200610639B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| EP1927350A1 (en) * | 2006-11-24 | 2008-06-04 | Novartis AG | Methods for improving bioavailability of a renin inhibitor |
| CA2769392A1 (en) | 2009-07-31 | 2011-02-03 | Sandoz Ag | Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method |
| WO2012010651A2 (en) | 2010-07-23 | 2012-01-26 | Sandoz Ag | Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method |
| WO2014168255A1 (ja) * | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 巨核球の成熟化促進物質 |
| WO2015035218A1 (en) * | 2013-09-05 | 2015-03-12 | Howard University | Method of increasing the bioavailability of an hiv drug |
| JP6029621B2 (ja) * | 2014-07-14 | 2016-11-24 | ヤマサ醤油株式会社 | 血漿レニン活性の測定法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108499A (en) | 1993-02-04 | 2000-02-29 | Lilly Co Eli | Mammalian influx peptide transporter |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| CA2224227A1 (en) | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| IL149360A0 (en) * | 1999-10-27 | 2002-11-10 | Baker Norton Pharma | Method and compositions for administering taxanes orally to human patients |
| WO2001058470A2 (en) * | 2000-02-11 | 2001-08-16 | Praecis Pharmaceuticals Incorporated | Methods for enhancing the bioavailability of a drug |
| AU2001271281A1 (en) * | 2000-05-31 | 2001-12-11 | Rutgers, The State University Of New Jersey | Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| GB0113663D0 (en) * | 2001-06-05 | 2001-07-25 | Novartis Ag | Use of organic compounds |
| HUP0402451A3 (en) | 2001-12-19 | 2008-04-28 | Alza Corp | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| US20040137054A1 (en) * | 2002-05-03 | 2004-07-15 | Alexandra Hager | Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors |
| DE60309472T2 (de) * | 2002-06-28 | 2007-06-28 | Speedel Pharma Ag | Pharmazeutische formulierung mit einem nicht peptidischen renin-hemmer und surfactant |
| US20080161321A1 (en) | 2004-03-17 | 2008-07-03 | David Louis Feldman | Use of Renin Inhibitors in Therapy |
-
2005
- 2005-08-01 PE PE2005000883A patent/PE20060416A1/es not_active Application Discontinuation
- 2005-08-01 AR ARP050103198A patent/AR050043A1/es not_active Application Discontinuation
- 2005-08-02 TW TW094126194A patent/TW200616610A/zh unknown
- 2005-08-02 DE DE602005017905T patent/DE602005017905D1/de active Active
- 2005-08-02 RU RU2007107850/15A patent/RU2404758C2/ru not_active IP Right Cessation
- 2005-08-02 EP EP05769973A patent/EP1776099B1/en active Active
- 2005-08-02 DK DK05769973.8T patent/DK1776099T3/da active
- 2005-08-02 MY MYPI20053584A patent/MY142180A/en unknown
- 2005-08-02 PT PT05769973T patent/PT1776099E/pt unknown
- 2005-08-02 CA CA2572743A patent/CA2572743C/en not_active Expired - Fee Related
- 2005-08-02 WO PCT/EP2005/008369 patent/WO2006013094A1/en active Application Filing
- 2005-08-02 BR BRPI0514021-8A patent/BRPI0514021A/pt not_active IP Right Cessation
- 2005-08-02 JP JP2007524264A patent/JP5134366B2/ja not_active Expired - Fee Related
- 2005-08-02 AU AU2005268844A patent/AU2005268844B2/en not_active Ceased
- 2005-08-02 US US11/572,471 patent/US7709532B2/en not_active Expired - Fee Related
- 2005-08-02 CN CN2005800261744A patent/CN1993116B/zh not_active Expired - Fee Related
- 2005-08-02 AT AT05769973T patent/ATE449601T1/de active
- 2005-08-02 PL PL05769973T patent/PL1776099T3/pl unknown
- 2005-08-02 SI SI200530915T patent/SI1776099T1/sl unknown
- 2005-08-02 ES ES05769973T patent/ES2335597T3/es active Active
- 2005-08-02 MX MX2007001339A patent/MX2007001339A/es active IP Right Grant
- 2005-08-02 EP EP09014648A patent/EP2191823A1/en not_active Withdrawn
- 2005-08-02 KR KR1020077002718A patent/KR20070040384A/ko active IP Right Grant
- 2005-08-02 NZ NZ552903A patent/NZ552903A/en not_active IP Right Cessation
-
2006
- 2006-12-18 ZA ZA200610639A patent/ZA200610639B/en unknown
-
2007
- 2007-01-11 IL IL180678A patent/IL180678A/en not_active IP Right Cessation
- 2007-01-15 EC EC2007007169A patent/ECSP077169A/es unknown
- 2007-02-02 TN TNP2007000038A patent/TNSN07038A1/en unknown
- 2007-02-22 MA MA29709A patent/MA28821B1/fr unknown
- 2007-02-28 NO NO20071142A patent/NO20071142L/no not_active Application Discontinuation
-
2010
- 2010-01-05 CY CY20101100019T patent/CY1109826T1/el unknown
- 2010-02-02 HR HR20100064T patent/HRP20100064T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100064T1 (hr) | Postupci za poboljšanje bioraspoloživosti inhibitora renina | |
| RS54258B1 (en) | SRC / ABL INHIBITOR FORMULATIONS | |
| HRP20120494T1 (hr) | Derivati purina za uporabu kao agonista adenozin a2a receptora | |
| HRP20020182B1 (hr) | Formulacije benzamida koje inhibiraju aktivnost histonskih deacetilaza | |
| RS52548B (en) | ORAL DOSAGE FORM CONTAINED BY PDE 4 INHIBITOR AS ACTIVE INGREDIENT AND POLYVINYL PYRILIDONE AS EXPIENT | |
| ATE374765T1 (de) | Substituierte heterocyclische amide | |
| HRP20161657T1 (hr) | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta | |
| MEP44308A (en) | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient | |
| HRP20130900T1 (hr) | Derivat (aza)indola i njegova uporaba u medicinske svrhe | |
| RS51664B (en) | PHARMACEUTICAL DOSAGE FORMS ABUSE-RESISTANT CONTAINING OPIOID ANALGETIC | |
| RU2000110737A (ru) | Производные бензамидина в качестве ингибиторов фактора xa | |
| AR037460A1 (es) | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion | |
| ME01395B (me) | Postupak za izradu (1s)-4,5-dimetoksi-1-(metilaminometil)benzociklobutanai njegovih aditivnih soli kiselina kao i njegov a primena za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina | |
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| RS54670B1 (en) | SOLID DOSAGE FORMULATION OF FENTANIL WITH IMPROVED BUCHAL ADSORPTION | |
| BRPI0506622A (pt) | éster biciclo derivado; um intermediário na produção do éster biciclo derivado; produto farmacêutico contendo um ingrediente ativo do éster biciclo derivado; inibidor dpp-iv contendo um ingrediente ativo do éster biciclo derivado; agente terapêutico para uma doença envolvendo dpp-iv contendo um ingrediente ativo do éster biciclo derivado, e agente terapêutico | |
| ATE440833T1 (de) | Antithrombotische diamide | |
| CZ304762B6 (cs) | (R)-2-Arylpropionamidové sloučeniny, jejich použití pro výrobu léčiva, farmaceutický prostředek s jejich obsahem a způsob jejich přípravy | |
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
| NO20020771L (no) | Peptidformulering med forlenget frigjöring | |
| EA200900827A1 (ru) | Фармацевтический состав, содержащий антагонист нейрокининов | |
| ATE261941T1 (de) | Heterocyclische amide als inhibitoren von faktor xa | |
| YU34396A (sh) | Farmaceutske smeše korisne za minimiziranje oštećenja kostiju | |
| BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
| ATE226934T1 (de) | Ester und amide als pla2-inhibitoren |